Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion type Assertion NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_head.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion evidence source_evidence_literature NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion SIO_000772 18843116 NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion wasDerivedFrom befree-20150227 NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.
- NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_assertion wasGeneratedBy ECO_0000203 NP889920.RA7gqrb044YIuLaXjjSgWYZSjcMv65nGnL01ekwY5nCe0130_provenance.